TY - JOUR
T1 - Long-term clinical outcomes after everolimus- and sirolimus-eluting coronary stent implantation
T2 - Final 3-year follow-up of the randomized evaluation of sirolimus-eluting versus everolimus-eluting stent trial
AU - Shiomi, Hiroki
AU - Kozuma, Ken
AU - Morimoto, Takeshi
AU - Igarashi, Keiichi
AU - Kadota, Kazushige
AU - Tanabe, Kengo
AU - Morino, Yoshihiro
AU - Akasaka, Takashi
AU - Abe, Mitsuru
AU - Suwa, Satoru
AU - Muramatsu, Toshiya
AU - Kobayashi, Masakazu
AU - Dai, Kazuoki
AU - Nakao, Koichi
AU - Uematsu, Masaaki
AU - Tarutani, Yasuhiro
AU - Fujii, Kenshi
AU - Simonton, Charles A.
AU - Kimura, Takeshi
PY - 2014/6
Y1 - 2014/6
N2 - Background-Long-term clinical outcomes of everolimus-eluting stent (EES) compared with sirolimus-eluting stent (SES) have not been evaluated fully yet, especially whether EES implantation could positively affect late adverse events reported after SES implantation occurring >1 year. Methods and Results-In this all-comer prospective multicenter randomized open-label trial, 3196 patients were assigned randomly to implant either EES (n=1596) or SES (n=1600). At 3 years, EES was noninferior to SES on the primary safety end point (all-cause death or myocardial infarction; 10.1% versus 11.5%; noninferiority P <0.001; and superiority P=0.19). Cumulative incidence of defnite stent thrombosis was low and was not signifcantly different between the 2 groups (0.5% versus 0.6%; P=0.81). There was no signifcant difference in the effcacy end point of target-lesion revascularization between the EES and SES groups (6.6% versus 7.9%; P=0.16). However, the cumulative incidence of target-lesion failure (cardiac death/target-vessel myocardial infarction/ischemia-driven target-lesion revascularization) was signifcantly lower in the EES group than in the SES group (8.8% versus 11.4%; P=0.01). By a landmark analysis at 1 year, the cumulative incidence of very late stent thrombosis and late target-lesion revascularization was not signifcantly different between the 2 groups (0.2% versus 0.2%; P=0.99 and 2.2% versus 2.9%; P=0.21, respectively). Conclusions-The effcacy and safety outcomes for this trial after EES implantation remained comparable with those after SES implantation through 3-year follow-up. However, improvement of clinical outcome after EES implantation compared with SES implantation was suggested by the signifcantly lower cumulative incidences of target-lesion failure, which has been the most widely used primary end point in the stent-versus-stent trials.
AB - Background-Long-term clinical outcomes of everolimus-eluting stent (EES) compared with sirolimus-eluting stent (SES) have not been evaluated fully yet, especially whether EES implantation could positively affect late adverse events reported after SES implantation occurring >1 year. Methods and Results-In this all-comer prospective multicenter randomized open-label trial, 3196 patients were assigned randomly to implant either EES (n=1596) or SES (n=1600). At 3 years, EES was noninferior to SES on the primary safety end point (all-cause death or myocardial infarction; 10.1% versus 11.5%; noninferiority P <0.001; and superiority P=0.19). Cumulative incidence of defnite stent thrombosis was low and was not signifcantly different between the 2 groups (0.5% versus 0.6%; P=0.81). There was no signifcant difference in the effcacy end point of target-lesion revascularization between the EES and SES groups (6.6% versus 7.9%; P=0.16). However, the cumulative incidence of target-lesion failure (cardiac death/target-vessel myocardial infarction/ischemia-driven target-lesion revascularization) was signifcantly lower in the EES group than in the SES group (8.8% versus 11.4%; P=0.01). By a landmark analysis at 1 year, the cumulative incidence of very late stent thrombosis and late target-lesion revascularization was not signifcantly different between the 2 groups (0.2% versus 0.2%; P=0.99 and 2.2% versus 2.9%; P=0.21, respectively). Conclusions-The effcacy and safety outcomes for this trial after EES implantation remained comparable with those after SES implantation through 3-year follow-up. However, improvement of clinical outcome after EES implantation compared with SES implantation was suggested by the signifcantly lower cumulative incidences of target-lesion failure, which has been the most widely used primary end point in the stent-versus-stent trials.
KW - Coronary restenosis
KW - Thrombosis
UR - http://www.scopus.com/inward/record.url?scp=84905829224&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84905829224&partnerID=8YFLogxK
U2 - 10.1161/CIRCINTERVENTIONS.113.001322
DO - 10.1161/CIRCINTERVENTIONS.113.001322
M3 - Article
C2 - 24803436
AN - SCOPUS:84905829224
SN - 1941-7640
VL - 7
SP - 343
EP - 354
JO - Circulation: Cardiovascular Interventions
JF - Circulation: Cardiovascular Interventions
IS - 3
ER -